Index condition

Interacting drugs recommended by any of the 12 guidelines

| Type 2 Diabetes | ACEI | ARB | K sparing diuretic | Spironolactone | Aldosterone antagonist | Alpha blocker | Thiazide | Loop diuretic | Nitrate | MAOI | Sodium Aurothiomalate | Beta-blocker | Ca channel blocker | Amiodarone | Sotalol | Flecainide | Domperidone | Reboxetine | Ciclosporin | Lithium | Digoxin | Theophylline | Antipsychotic | Clopidogrel | Dabigatran | Phenindione | Statin | NSAIDs | Warfarin |
|-------------------------------------|------|-----|--------------------|----------------|------------------------|---------------|----------|---------------|---------|------|-----------------------|--------------|--------------------|------------|---------|------------|-------------|------------|-------------|---------|---------|--------------|---------------|-------------|------------|-------------|--------|--------|----------|
| Metformin | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sulfonglurea | | | | | | | | | | | | | | | | | | | | | | | | | | | | Р | Р |
| ACE Inhibitor | | | K+ | K+ | K+ | | BP- | BP- | | | BP- | | | | | | | | K+ | Р | | | | | | | | | |
| Simvastatin / Atorvastatin | | | | | | | | | | | | | M | M | | | | | M | | | | | | | | | | |
| ARB for hypertension | | | K+ | K• | K+ | | BP- | BP- | | | | | | | | | | | K+ | Р | | | | | | | | | |
| Ca channel blocker for hypertension | | | | | | BP- | | | | | | HR- | | HB- | HB- | HB- | | | P | | Р | Р | | | В | | M | | |
| Diuretic for hypertension | BP- | BP- | | | | BP- | | | | | | | | | K- | K- | | | | P | K- | | | | | | | | |
| Alpha blocker for hypertension | | | BP- | BP- | | | BP- | BP- | | BP- | | BP- | BP- | | BP- | | | | | | | | | | | | | | |
| Beta blocker for hypertension | | | | | | BP- | | | | | | | HB- | HR- | | HB- | | | Р | | | | | | | | | | |
| K-sparing diuretic for hypertension | K+ | K+ | | | | | | | | | | | | | | | | | | Р | | | | | | | | | |
| Other statins | | | | | | | | | | | | | | | | | | | M | | | | | | | В | | | Р |
| Fibrate | | | | | | | | | | | | | | | | | | | | | | | | | | В | M | | Р |
| Erythromycin | | | | | | | | | | | | | Р | | | | HB+ | Р | P | | | Р | P | В | | | M | | В |
| PPDE5 inhibitor | | | | | | BP- | | | BP- | | | | | | | | | | | | | | | | | | | | |
| Metoclopramide | | | | | | | | | | | | | | | | | | | P | | | | | | | | | | |
| Domperidone | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ezetemibe | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Omega-3 fish oil | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| DPP-4 inhibitor/gliptin | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Thiazolidinedione | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| GLP-1 mimetic (exenatide) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Acarbose | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Insulin | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Index condition

Interacting drugs recommended by any of the 12 guidelines

| Depression | Aspirin | Warfarin | NSAID | Dabigatran | Clopidogrel | Alphablocker | Theophylline | ARB | Ace Inhibitor | Diuretics | Lithium | Bupropion | codeine/dihydrocodeine | MAOI | Moclobemide | Tramadol | TCA | Antipsychotic | Erythromycin | Amiodarone | Flecainide | Propafenone | Sotalol |
|---|---------|----------|-------|------------|-------------|--------------|--------------|-----|---------------|-----------|---------|-----------|------------------------|------|-------------|----------|-----|---------------|--------------|------------|------------|-------------|---------|
| SSRI | В | В | В | В | В | | Р | | | | Р | | | CNS | CNS | CNS | VA | VA | | | | | |
| Venlafaxine | В | В | В | В | | | | | | | | | | CNS | CNS | | | VA | | | | | |
| Mirtazapine | | | | | | | | | | | | | | CNS | CNS | | | | | | | | |
| Duloxetine | | | | В | | | | | | | | | | CNS | CNS | | | | | | | | |
| Reboxetine | | | | | | | | | | | | | | CNS | | | | | | | | | |
| Flupentixol | | | | | | | | | | | | | | | | | | | | | | | |
| Tryptophan | | | | | | | | | | | | | | CNS | | | | | | | | | |
| TCA | | В | | | | | | | | | | | | CNS | CNS | CNS | | VA | | VA | VA | VA | VA |
| MAOI | | | | | | ВР | | | | | | CNS | CNS | CNS | CNS | CNS | CNS | CNS | | | | | |
| Moclobemide | | | | | В | | | | | | | CNS | CNS | CNS | | | CNS | | | | | | |
| Lithium | | | Р | | | | | Р | Р | Р | | | | | | | | | | VA | | | |
| Antipsychotic (aripiprazole, olanzapine, quetiapine, risperidone) | | | | | | | | | | VA | | | | | | | VA | VA | VA | VA | VA | | VA |

Index condition Interacting drugs recommended by any of the 12 guidelines

| HEART FAILURE | Alpha blocker | Sodium Aurothiomalate | PPDE5 inhibitor | Diuretic for BP | ACE Inhibitor | Angiotensin-II receptor antagonist | Digoxin | K+sparing diuretic | Flecainide | Sotalol | Amisulpride / Pimozide | Amiodarone | Propafenone | Ciclosporin | Verapamil | Diltiazem / Nifedipine | Nicardipine | Hydroxychloroquine Chloroquine | Lithium | Theophylline | Methotrexate | Phenindione | NSAIDs / COX2 | SSRI | Venlafaxine | Erythromycin | Simvastatin | Sulphonylurea | Aspirin Azathioprine Clopidogrel Dabigatran Esomeprazole Fibrates Fibrates Fluxastatin Omeprazole Rosuvastatin TCA Tramadol |
|---------------------------------------|---------------|-----------------------|-----------------|-----------------|---------------|---------------------------------------|---------|--------------------|------------|---------|------------------------|------------|-------------|-------------|-----------|------------------------|-------------|-----------------------------------|---------|--------------|--------------|-------------|---------------|------|-------------|--------------|-------------|---------------|---|
| Licenced Betablocker | BP- | | | | | | | | HR- | | | HR- | HR- | Р | BP- | HR- | | | | | | | | | | | | | |
| ACEI | | BP- | | BP- | | | | НК | | | | | | НК | | | | | Р | | | | | | | | | | |
| Aldosterone antagonist | | | | | НК | НК | Р | HK | | | | | | НК | | | | | Р | | | | | | | | | | |
| Digoxin | | | | LK | | | | | | | | Р | Р | Р | Р | Р | Р | Р | | | | | | | | | | | |
| Angiotensin-II receptor antagonist | | | | BP- | | | | НК | | | | | | НК | | | | | Р | | | | | | | | | | |
| Hydralazine | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Nitrate | | | BP- | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Loop diuretic | BP- | | | | BP- | BP- | LK | | LK | LK | LK | | | | | | | | Р | | | | | | | | | | |
| Warfarin | | | | | | | | | | | | В | В | | | | | | | | | | В | В | В | В | | Р | В |
| Aspirin | | | | | | | | | | | | | | | | | | | | | Р | В | В | В | В | | | | |
| Amlodipine | BP- | | | | | | | | | | | | | | | | | | | Р | | | | | | Р | М | | |

Key: BP- = hypotensive effect; B=bleeding; HR-= bradycardia; VA = ventricular arrhythmias; LK/HK = effect on serum potassium; P= clinically significant altered plasma concentration which might require dosage alteration or closer monitoring; M=myopathy; CNS = central nervous system toxicit